The assimilation of western medicine into a semi-nomadic healthcare system: A case study of the indigenous Aeta Magbukún, Philippines

The Aeta Magbukún are a genetically and culturally distinct group of Indigenous people living in an isolated mountain forest in the municipality of Mariveles, in the province of Bataan, Philippines. This research aims to document some healthcare related information of the people, inform future decisions regarding maximising benefits of modern conveniences, and minimise negative consequences on their culture and health. Using an ethnographic approach, data were collated from a community health survey in combination with field notes from three of the co-authors while living with the Aetas. Despite major implications from rapid ecological and cultural changes, traditional ethnomedical systems continue to be revered as an essential healing practice, although they are increasingly used in conjunction with Western medicines and healthcare. At the Aeta village level, the changing socio-political influence among the kagun (traditional healer), the NGOs, and the Municipal Council in terms of healthcare provision is pivotal, as the kagun has chosen to integrate the Western medicine and healthcare services into their traditional healthcare system, without simply rejecting them. In turn, Western-style healthcare interventions have the potential to be carefully managed to integrate traditional Aeta Magbukún socio-political structures, healthcare, and cultural continuity. The cumulative influence of numerous other novel aspects to Aeta life (e.g., permanent housing, a highway through the village, literacy, cash economies, energy-dense foods, communication/entertainment devices, etc.) will place additional pressure on the traditional ethnomedical healthcare system. However, enabling the continuity of access to appropriate healthcare knowledge (both the transfer of knowledge from Western medicine to the Aeta Magbukún, and vice versa) can assist many cultures through the inherent stresses of increasingly rapid acculturation and development

Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.

none18BACKGROUND: Inflammatory bowel disease (IBD) frequently affects women during their reproductive years. Pregnancy outcome in women with IBD is well described, particularly in retrospective studies. AIM: To evaluate the pregnancy outcome in patients with IBD in a prospective European multicentre case-control study. METHODS: Inflammatory bowel disease pregnant women from 12 European countries were enrolled between January 2003 and December 2006 and matched (1:1) to non-IBD pregnant controls by age at conception and number of previous pregnancies. Data on pregnancy and newborn outcome, disease activity and therapy were prospectively collected every third month using a standard questionnaire. Logistic regression analysis with odds ratio was used for statistical analyses. P value<0.05 was considered significant. RESULTS: A total of 332 pregnant women with IBD were included: 145 with Crohn's disease (CD) and 187 with ulcerative colitis (UC). Median age (range) at conception was 31 years (15-40) in CD and 31 (19-42) in UC patients. No statistically significant differences in frequency of abortions, preterm deliveries, caesarean sections, congenital abnormalities and birth weight were observed comparing CD and UC women with their non-IBD controls. In CD, older age was associated with congenital abnormalities and preterm delivery; smoking increased the risk of preterm delivery. For UC, older age and active disease were associated with low birth weight; while older age and combination therapy were risk factors for preterm delivery. CONCLUSION: In this prospective case-control study, women with either Crohn's disease or ulcerative colitis have a similar pregnancy outcome when compared with a population of non-inflammatory bowel disease pregnant women.noneBortoli A;Pedersen N;Duricova D;D'Inca R;Gionchetti P;Panelli MR;Ardizzone S;Sanroman AL;Gisbert JP;Arena I;Riegler G;Marrollo M;Valpiani D;Corbellini A;Segato S;Castiglione F;Munkholm P;European Crohn-Colitis Organisation (ECCO) Study Group of Epidemiologic Committee (EpiCom)Bortoli A;Pedersen N;Duricova D;D'Inca R;Gionchetti P;Panelli MR;Ardizzone S;Sanroman AL;Gisbert JP;Arena I;Riegler G;Marrollo M;Valpiani D;Corbellini A;Segato S;Castiglione F;Munkholm P;European Crohn-Colitis Organisation (ECCO) Study Group of Epidemiologic Committee (EpiCom

Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.

BACKGROUND: Inflammatory bowel disease (IBD) frequently affects women during their reproductive years. Pregnancy outcome in women with IBD is well described, particularly in retrospective studies. AIM: To evaluate the pregnancy outcome in patients with IBD in a prospective European multicentre case-control study. METHODS: Inflammatory bowel disease pregnant women from 12 European countries were enrolled between January 2003 and December 2006 and matched (1:1) to non-IBD pregnant controls by age at conception and number of previous pregnancies. Data on pregnancy and newborn outcome, disease activity and therapy were prospectively collected every third month using a standard questionnaire. Logistic regression analysis with odds ratio was used for statistical analyses. P value<0.05 was considered significant. RESULTS: A total of 332 pregnant women with IBD were included: 145 with Crohn's disease (CD) and 187 with ulcerative colitis (UC). Median age (range) at conception was 31 years (15-40) in CD and 31 (19-42) in UC patients. No statistically significant differences in frequency of abortions, preterm deliveries, caesarean sections, congenital abnormalities and birth weight were observed comparing CD and UC women with their non-IBD controls. In CD, older age was associated with congenital abnormalities and preterm delivery; smoking increased the risk of preterm delivery. For UC, older age and active disease were associated with low birth weight; while older age and combination therapy were risk factors for preterm delivery. CONCLUSION: In this prospective case-control study, women with either Crohn's disease or ulcerative colitis have a similar pregnancy outcome when compared with a population of non-inflammatory bowel disease pregnant women

A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy

We have examined the potential of recombinant Escherichia coli expressing listeriolysin 0 (LLO) to deliver tumour antigens to dendritic cells (DCs) for cancer immunotherapy. Using OVA as a model tumour antigen, we have shown in murine DCs that E. coli expressing cytoplasmic LLO and OVA proteins can deliver the OVA K-b-restricted epitope SIINFEKL for MHC class I presentation. In contrast, when E coli expressing OVA alone were used, MHC class II presentation of the OVA 323-339 I-A(b)-restricted peptide was predominant When injected in vivo, DCs pulsed with E coli expressing LLO and OVA induced production of cytotoxic T-lymphocytes capable of lysing an OVA-expressing melanoma cell line (B16-OVA) and resulted in suppression of tumour growth following challenge with B16-OVA. Immunisation of mice by direct injection of E coli LLO/OVA provided a more potent anti-tumour response, resulting in complete protection in 75% of mice. Injection of live bacteria was not necessary as immunisation with paraformaldehyde-fixed E coli LLO/OVA provided an even stronger anti-tumour response against B16-OVA. Altogether, our data highlight the potential of this system as a novel and efficient strategy for tumour immunotherapy